News
DWK Life Sciences to supply glass vials for UK vaccine development
DWK Life Sciences will provide the VMIC with borosilicate pharmaceutical glass vials which can be used to store vaccines.
The VMIC was set up to provide the UK’s first strategic vaccine development and advanced manufacturing capability and has taken a...
News
Kindred Bio Expands of Manufacturing Agreement with Vaxart for COVID-19 Vaccine
Kindred Biosciences, Inc., a biopharmaceutical company developing novel biologics, announced it has expanded an agreement with Vaxart, Inc. for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur...
News
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Trial
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV® (enfortumab vedotin-ejfv) for patients...
News
Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA
Merck, a leading science and technology company, announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada and Takara Bio USA, Inc., a biotechnology company based...
News
Direct Biologics Granted Expanded Access by FDA for ExoFlo in the Treatment of COVID-19
Direct Biologics, LLC, announced that the FDA has granted expanded access for ExoFlo in the treatment of patients with COVID-19 associated acute respiratory distress syndrome (ARDS).
While Direct Biologics is already enrolling patients in EXIT COVID-19, its national multi-center, Phase...
Clinical Trials
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been...
News
Gilead Sciences signs joint procurement agreement with the European Commission for Veklury (remdesivir)
Gilead Sciences and the EC signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU)....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
